Illinois Municipal Retirement Fund Purchases Shares of 93,479 Amneal Pharmaceuticals, Inc. $AMRX

Illinois Municipal Retirement Fund purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 93,479 shares of the company’s stock, valued at approximately $1,162,000.

Several other institutional investors and hedge funds have also made changes to their positions in AMRX. Artemis Investment Management LLP acquired a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $1,574,000. SG Americas Securities LLC increased its holdings in shares of Amneal Pharmaceuticals by 2,866.0% in the fourth quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock valued at $9,889,000 after purchasing an additional 758,343 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of Amneal Pharmaceuticals in the first quarter worth about $936,000. Assenagon Asset Management S.A. raised its stake in shares of Amneal Pharmaceuticals by 75.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after purchasing an additional 1,611,698 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter worth about $921,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AMRX shares. UBS Group upped their target price on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Finally, Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.60.

Amneal Pharmaceuticals Stock Down 1.9%

Shares of AMRX opened at $17.75 on Thursday. The company has a market capitalization of $5.66 billion, a price-to-earnings ratio of 46.71 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.66 and a 52 week high of $18.39. The stock’s 50-day moving average price is $15.36 and its 200-day moving average price is $14.00.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million during the quarter. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.30% of the stock is owned by insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.